JP6805172B2 - ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 - Google Patents
ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 Download PDFInfo
- Publication number
- JP6805172B2 JP6805172B2 JP2017557324A JP2017557324A JP6805172B2 JP 6805172 B2 JP6805172 B2 JP 6805172B2 JP 2017557324 A JP2017557324 A JP 2017557324A JP 2017557324 A JP2017557324 A JP 2017557324A JP 6805172 B2 JP6805172 B2 JP 6805172B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- mixture
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*N(*N(*)*)C(c(*(C)c1)**c1-c1n[o]c(C(F)(F)F)n1)=O Chemical compound C*N(*N(*)*)C(c(*(C)c1)**c1-c1n[o]c(C(F)(F)F)n1)=O 0.000 description 2
- MLTZNSHLFMSOPY-HNNXBMFYSA-N C[C@@H](CCC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O)CN1CCC2(CC2)CC1 Chemical compound C[C@@H](CCC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O)CN1CCC2(CC2)CC1 MLTZNSHLFMSOPY-HNNXBMFYSA-N 0.000 description 1
- NLDCYGWSPPNJSB-GFCCVEGCSA-N C[C@H](C(N(CC1)Cc2c1cccc2)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](C(N(CC1)Cc2c1cccc2)=O)NC(OC(C)(C)C)=O NLDCYGWSPPNJSB-GFCCVEGCSA-N 0.000 description 1
- QVHJQCGUWFKTSE-RXMQYKEDSA-N C[C@H](C(O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](C(O)=O)NC(OC(C)(C)C)=O QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 1
- KUENUWACNZYNKC-SNVBAGLBSA-N C[C@H](CN(CC1)Cc2c1cccc2)N Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)N KUENUWACNZYNKC-SNVBAGLBSA-N 0.000 description 1
- ATPMCQLSQHGRHW-CYBMUJFWSA-N C[C@H](CN(CC1)Cc2c1cccc2)NC(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)NC(OC(C)(C)C)=O ATPMCQLSQHGRHW-CYBMUJFWSA-N 0.000 description 1
- OYXHJSOZEXCCIB-CQSZACIVSA-N C[C@H](CN(CC1)Cc2c1cccc2)NC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O Chemical compound C[C@H](CN(CC1)Cc2c1cccc2)NC(c(cc1)ccc1-c1n[o]c(C(F)(F)F)n1)=O OYXHJSOZEXCCIB-CQSZACIVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158363P | 2015-05-07 | 2015-05-07 | |
| US62/158,363 | 2015-05-07 | ||
| PCT/US2016/031335 WO2016179554A1 (en) | 2015-05-07 | 2016-05-06 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515489A JP2018515489A (ja) | 2018-06-14 |
| JP2018515489A5 JP2018515489A5 (enExample) | 2019-06-13 |
| JP6805172B2 true JP6805172B2 (ja) | 2020-12-23 |
Family
ID=57218014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557324A Active JP6805172B2 (ja) | 2015-05-07 | 2016-05-06 | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10053434B2 (enExample) |
| EP (1) | EP3291810B1 (enExample) |
| JP (1) | JP6805172B2 (enExample) |
| KR (1) | KR20180002729A (enExample) |
| CN (1) | CN107735088B (enExample) |
| AU (1) | AU2016258188B2 (enExample) |
| CA (1) | CA2984618C (enExample) |
| EA (1) | EA036965B1 (enExample) |
| IL (1) | IL255448B2 (enExample) |
| MX (1) | MX378983B (enExample) |
| WO (1) | WO2016179554A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2984618C (en) * | 2015-05-07 | 2024-01-09 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| WO2018015447A1 (en) * | 2016-07-22 | 2018-01-25 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN109627207A (zh) * | 2018-12-17 | 2019-04-16 | 天津药明康德新药开发有限公司 | 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法 |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| WO2022174193A1 (en) * | 2021-02-15 | 2022-08-18 | The Research Foundation For The State University Of New York | Radiolabeled compositions and methods of use thereof |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061638A2 (en) | 2004-12-10 | 2006-06-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Heterocycle derivatives as histone deacetylase (hdac) inhibitors |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EA201490228A1 (ru) * | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| SG2014012926A (en) * | 2011-08-30 | 2014-06-27 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013066835A2 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| CA2856334A1 (en) * | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| JP6275690B2 (ja) * | 2012-04-05 | 2018-02-07 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
| EA035592B1 (ru) | 2015-05-07 | 2020-07-13 | Сиэйчдиай Фаундэйшн, Инк. | Ингибиторы деацетилаз гистонов и композиции и способы их применения |
| CA2984618C (en) * | 2015-05-07 | 2024-01-09 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| HRP20230052T1 (hr) | 2015-07-27 | 2023-03-03 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
-
2016
- 2016-05-06 CA CA2984618A patent/CA2984618C/en active Active
- 2016-05-06 WO PCT/US2016/031335 patent/WO2016179554A1/en not_active Ceased
- 2016-05-06 US US15/148,907 patent/US10053434B2/en active Active
- 2016-05-06 CN CN201680040061.8A patent/CN107735088B/zh active Active
- 2016-05-06 EP EP16790203.0A patent/EP3291810B1/en active Active
- 2016-05-06 KR KR1020177034461A patent/KR20180002729A/ko not_active Withdrawn
- 2016-05-06 AU AU2016258188A patent/AU2016258188B2/en active Active
- 2016-05-06 JP JP2017557324A patent/JP6805172B2/ja active Active
- 2016-05-06 MX MX2017014300A patent/MX378983B/es unknown
- 2016-05-06 EA EA201792247A patent/EA036965B1/ru not_active IP Right Cessation
-
2017
- 2017-11-06 IL IL255448A patent/IL255448B2/en unknown
-
2018
- 2018-07-26 US US16/046,254 patent/US20190202795A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL255448B2 (en) | 2023-07-01 |
| HK1252487A1 (en) | 2019-05-24 |
| US20190202795A1 (en) | 2019-07-04 |
| IL255448B1 (en) | 2023-03-01 |
| BR112017023711A2 (pt) | 2018-07-17 |
| WO2016179554A1 (en) | 2016-11-10 |
| MX378983B (es) | 2025-03-10 |
| CN107735088B (zh) | 2021-11-02 |
| EP3291810B1 (en) | 2022-08-10 |
| US20160326124A1 (en) | 2016-11-10 |
| CA2984618A1 (en) | 2016-11-10 |
| IL255448A0 (en) | 2017-12-31 |
| JP2018515489A (ja) | 2018-06-14 |
| EP3291810A1 (en) | 2018-03-14 |
| CN107735088A (zh) | 2018-02-23 |
| AU2016258188A1 (en) | 2017-11-23 |
| CA2984618C (en) | 2024-01-09 |
| MX2017014300A (es) | 2018-08-09 |
| EP3291810A4 (en) | 2018-11-07 |
| EA036965B1 (ru) | 2021-01-20 |
| AU2016258188B2 (en) | 2021-08-26 |
| US10053434B2 (en) | 2018-08-21 |
| KR20180002729A (ko) | 2018-01-08 |
| EA201792247A1 (ru) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6782255B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| JP7644517B2 (ja) | Ｋｒａｓ突然変異型タンパク質阻害剤 | |
| CN107735088B (zh) | 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 | |
| CN120077051A (zh) | Kras抑制剂 | |
| CN113631557A (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
| AU2023202086A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
| BR112014030655B1 (pt) | compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende | |
| KR20180110132A (ko) | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 | |
| MX2013008629A (es) | Inhibidores de histona desacetilasa y composiciones y metodos para su uso. | |
| EP2976341A1 (en) | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | |
| TW201514135A (zh) | 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法 | |
| CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
| CN119546607A (zh) | Lrrk2抑制剂 | |
| HK1252487B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| BR112017023711B1 (pt) | Inibidores de histona deacetilase e composições e métodos de uso dos mesmos | |
| WO2020207352A1 (zh) | 三嗪酮并咪唑类化合物及其医药用途 | |
| HK1252489B (en) | Histone deacetylase inhibitors and compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190507 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200407 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201001 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20201001 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201009 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201013 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6805172 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |